EverZom

Biotech & Life Sciences · Paris, France · Founded 2019

A key asset to the future health of an ageing population MoreLess

Developer of a GMP-compliant extracellular vesicle manufacturing platform based on a unique proprietary technology designed for pharmaceutical researchers. The company's extracellular vesicles have protective and reparative properties representing an important therapeutic tool, thereby enabling healthcare professionals to use them to overcome the failure of an organ, restoring its function and homeostasis. Keywords: Pharmaceuticals and Biotechnology, Bio Medicine Company, Bio Medicine Platform, Bio Production Systems, Biomedical Research, Bioproduction Facility, Nanomedecine Biotech Company, Regenerative Medicine.

Valuation $0–100M

Headcount <100

Total funding $10–50M

Unlock exact values

Company overview

EverZom company information

The essential company record, classifications and operating signals in one place.

Status: Operational
Founded: 2019
Headquarters: Paris, France
Employees: 24
Open positions: None listed
Dealroom signal: 84.2

Website ↗LinkedIn ↗

client focusb2bsub industryBioTechnologysub industryHealth Platformbusiness modelManufacturingindustryHealthsectorBiotechnologysectorDrug DevelopmentsectorRegenerative MedicinesectorSpinoutsectorEICsectorBiotech and PharmasectorEIC FundsectorEIT Healthsectorbiotech medtech and e-health

Valuation & funding

EverZom funding history

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VC✓Equity / VC	Oct 2025	$11M	$44M	Paris Business Angels · Capital Cell · Sorbonne Venture · Capital Grand Est	↗
EARLY VC✓Equity / VC	Aug 2025	$0	—	EIC Fund	—
SUPPORT PROGRAM✓Other financing	Jan 2022	$0	—	EIT Health	—
EARLY VC✓Equity / VC	Jun 2021	$0	—	EIC Fund	—
GRANT✓Other financing	Jun 2021	$1.7M	—	European Innovation Council	—
SEED✓Equity / VC	Dec 2020			Bpifrance	↗
SPINOUT✓Other financing	Sep 2019			Paris-Cité University	↗
GRANTOther financing	Sep 2019			Undisclosed	—
SUPPORT PROGRAM✓Other financing	Feb 2019			HEC Challenge+ · HEC Paris	—

Showing 9 recorded eventsUnlock the complete deal history →

Financials

Workforce over time

Available workforce history. Financial fields without reported data are omitted.

Year	Employees
2026	24
2025	19
2024	15
2023	19
2022	19

Company filings, research estimates and Dealroom dataOpen the full financial model →

Growth signals

EverZom website traffic

Latest recorded traffic for EverZom is 920 monthly website visits, down 56.2% over the last three months. EverZom's team grew 26.3% over the past year.

Latest monthly visits920 3-month web change-56.2% 1-year team growth+26.3%

Monthly website visits63 observations · Oct 2020–Jul 2026

Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

EverZom compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
QPQubit PharmaceuticalsQuantum physics and AI-driven drug discovery platform	Paris, France	Operational	57	$26M	$70M
SISmart ImmuneDevelops off-the-shelf allogeneic T-cell progenitor therapies to restore a fully functional immune system in patients with cancer and severe infections	Paris, France	Operational
OMOMINIOmini develops biosensing devices for immediate blood tests at the patient bedside	Paris, France	Operational
THTHERAPANACEADevotion to Innovation, Compassion for Patients, Artificial Intelligence for Cancer Care	Paris, France	Operational
GRGraphealGrapheal develops and manufactures true monolayer graphene on flexible substrates, enabling next-generation sustainable and cost-effective sensor platforms especially when coupled with IOTs	Grenoble, France	Operational
MAMAbSilicoComputational solutions for antibody discovery using Artificial Intelligence and Machine Learning	Tours, France	Operational
SLScienta LabAI-powered Precision Immunology	Gif-sur-Yvette, France	Operational
HEHealshapePersonalized, resorbable bioprosthesis for natural breast reconstruction	Nantes, France	Operational

Showing 8 of the closest matchesCompare every metric →

Talent graph

EverZom's talent

Book a demo to see the people

Team profiled 11 named & role-tagged

Founders /100 quality score

Key operators 5 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

15 investors on EverZom's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Seed 2 investors entered at this stage

Bpifrance

European Innovation Council

Series A 7 investors entered at this stage

EIC Fund

Capital Grand Est

Paris Business Angels

Capital Cell

Sorbonne Venture

Aloe Private Equity

EISMEA

Other known 6 additional known investors

HEC Paris

EIT Health

HEC Challenge+

Paris-Cité University

Erganeo

Paris Biotech Santé

Global footprint

Where EverZom has talent and traffic

Workforce by country

2 countries with
team presence

🇫🇷 France95.7%

🇧🇪 Belgium4.3%

2 countries shown

In the news

Latest news about EverZom

Recent press, funding announcements, and product moves mentioning EverZom — open to read from the original sources.

See all news

Market sentiment

What the market is saying about EverZom

An AI-synthesized read of the highest-engagement posts about EverZom on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See EverZom’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.